TY - JOUR
AU - Katsura, Toshiya
AB - Clin Pharmacokinet (2013) 52:593–609 DOI 10.1007/s40262-013-0058-5 OR IGINAL RESEARCH ARTIC L E Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer • • • • Masahide Fukudo Yasuaki Ikemi Yosuke Togashi Katsuhiro Masago • • • • Young Hak Kim Tadashi Mio Tomohiro Terada Satoshi Teramukai • • Michiaki Mishima Ken-ichi Inui Toshiya Katsura Published online: 27 March 2013 Springer International Publishing Switzerland 2013 Abstract mutations if available, were examined. Early exposure to Background Erlotinib shows large inter-patient pharma- erlotinib and its safety/efficacy relationship were evaluated. cokinetic variability, but the impact of early drug exposure Results The apparent clearance of erlotinib and OSI-420 and genetic variations on the clinical outcomes of erlotinib were significantly decreased by 24 and 35 % in patients remains fully investigated. The primary objective of this with the ABCG2 421A allele, respectively (p \ 0.001), study was to clarify the population pharmacokinetics/ while ABCB1 and CYP3A5 polymorphisms did not affect pharmacodynamics of erlotinib in Japanese patients with their apparent clearance. The ABCG2 421A allele was non-small cell lung cancer (NSCLC). The secondary significantly associated with increased CSF penetration for objective was to 
TI - Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer
JF - Clinical Pharmacokinetics
DO - 10.1007/s40262-013-0058-5
DA - 2013-03-27
UR - https://www.deepdyve.com/lp/springer-journals/population-pharmacokinetics-pharmacodynamics-of-erlotinib-and-dE5aYoOhHp
SP - 593
EP - 609
VL - 52
IS - 7
DP - DeepDyve
ER -